The Technical Analyst
RayzeBio, Inc. Common [RYZB]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
RayzeBio, Inc. Common Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.02% $62.49
America/New_York / 23 feb 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3 750.42 mill |
| EPS: | -1.080 |
| P/E: | -57.86 |
| Earnings Date: | Mar 04, 2024 |
| SharesOutstanding: | 60.02 mill |
| Avg Daily Volume: | 0.745 mill |
| RATING 2024-02-23 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||
|---|---|---|---|---|
| 3/22 | 4/22 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | |
| Asset | n/a | n/a | n/a | |
| Debt | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -57.86 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -9.84x |
| Company: PE -57.86 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 62.04 - 62.95 ( +/- 0.73%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-26 | Viking Global Investors Lp | Sell | 1 743 556 | Common Stock |
| 2023-09-19 | Redmile Group, Llc | Buy | 498 510 | Common Stock |
| 2023-09-19 | Redmile Group, Llc | Buy | 494 687 | Common Stock |
| 2023-09-19 | Redmile Group, Llc | Buy | 864 509 | Common Stock |
| 2023-09-19 | Redmile Group, Llc | Sell | 498 510 | Series D Preferred Stock |
| INSIDER POWER |
|---|
| -34.76 |
| Last 21 transactions |
| Buy: 7 015 868 | Sell: 14 005 880 |
Forecast:
01:40 - $72.57
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $62.49 (0.02% ) |
| Volume | 0.283 mill |
| Avg. Vol. | 0.745 mill |
| % of Avg. Vol | 37.92 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For RYZB
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $62.26 | N/A | Active |
|---|
RYZB
RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company’s lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California.
Latest Press Releases
2024-02-26 08:35:00 - Press Release
Bristol Myers Squibb Completes Acquisition Of Rayzebio, Adding Differentiated Actinium-based Radiopharmaceutical Platform
Princeton, n.j.--(business wire)--bristol myers squibb (nyse: bmy) announced today that it has successfully completed its acquisition of rayzebio, inc. (nasdaq: ryzb). with the completion of the acquisition, rayzebio shares have ceased trading on the nasdaq global market and rayzebio is now a wholly owned subsidiary of bristol myers squibb. “we are excited to complete this transaction, which adds radiopharmaceutical therapeutics (rpts), one of the fastest-growing new modalities for treating pat.
2024-02-23 06:59:00 - Press Release
Bristol Myers Squibb Announces Expiration Of Rayzebio Tender Offer
Princeton, n.j.--(business wire)--bristol myers squibb (nyse: bmy) today announced that its previously announced tender offer (the “offer”) to acquire all of the outstanding shares of rayzebio, inc. (nasdaq: ryzb) common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion, expired at one minute after 11:59 p.m., eastern time, on february 22, 2024 (the “expiration time”). equiniti trust company, the depositary for the offer, has advised that, as of the expiratio.
2024-02-12 06:59:00 - Press Release
Bristol Myers Squibb And Rayzebio Announce Expiration Of Hsr Act Waiting Period
Princeton, n.j. & san diego--(business wire)--bristol myers squibb (nyse: bmy) and rayzebio, inc. (nasdaq: ryzb) today announced the expiration of the waiting period under the hart-scott-rodino antitrust improvements act of 1976, or hsr act, in connection with bristol myers squibb's previously announced tender offer to acquire all of the outstanding shares of rayzebio common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion. the expiration of the waiting peri.
2023-12-31 17:56:00 - Press Release
Rayzebio Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Rayzebio, Inc. - Ryzb
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of rayzebio, inc. (nasdaqgm: ryzb) to bristol-myers squibb company (nyse: bmy). under the terms of the proposed transaction, shareholders of rayzebio will receive $62.50 in cash for each share of rayzebio that they own. ksf is seeking to determine whether this consideration and the process that led to it are adeq.
2023-12-26 10:45:00 - Press Release
Shareholder Alert: Ademi Llp Investigates Whether Rayzebio, Inc. Has Obtained A Fair Price In Its Transaction With Bristol Myers
Milwaukee , dec. 26, 2023 /prnewswire/ -- ademi llp is investigating rayzebio (nasdaq: ryzb) for possible breaches of fiduciary duty and other violations of law in its transaction with bristol myers. click here to learn how to join the https://www.ademilaw.com/case/rayzebio-inc or call guri ademi toll-free at 866-264-3995.
Latest News
2024-01-08 07:03:12 - MarketBeat
IPO watch 2024: Which new stocks will hit the market?
Among 2023 IPOs, one of the top performers was RayzeBio Inc. NASDAQ: RYZB, a biotech that's out of play now because it's being acquired by Bristol Myers Squibb Co. NYSE: BMY.
2023-12-27 07:50:00 - Market Watch
Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target
Fusion Pharmaceuticals Inc.'s stock FUSN, +16.69% was up by 5.3% in premarket trading on Wednesday, as analysts at Oppenheimer highlighted the company as a potential merger target. Fusion Pharmaceuticals “is potentially the sole remaining clinical-stage, targeted radiopharm player with a robust supply chain,” analysts said in a research note on Wednesday.
2023-12-26 18:47:04 - Zacks Investment Research
Yes Virginia, There Is a Santa Claus Rally
The Russell is up an astounding +26% from late October, largely thanks to signaled interest rate cuts from the Fed in 2024.
2023-12-26 14:46:38 - Bloomberg Markets and Finance
Bristol to Buy Drug Developer RayzeBio for $4.1 Billion
Bristol Myers Squibb Co. agreed to buy radiological drug developer RayzeBio Inc. for about $4.1 billion, the latest deal in a buying spree to bolster its pipeline. Bloomberg's Madison Mueller reports.
2023-12-26 14:01:58 - CNBC Television
The state of pharmaceuticals: Bristol-Myers Squibb's plan to buy RayzeBio
Jared Hopkins, Wall Street Journal, joins 'The Exchange' to discuss Bristol-Myers Squibb's plan to buy RayzeBio.
2023-12-26 12:15:51 - Investopedia
Bristol Myers Squibb Buys RayzeBio, Its Second Multibillion-Dollar Deal in Days
RayzeBio Inc. (RYZB) shares skyrocketed Tuesday after Bristol Myers Squibb Co. (BMY) said it was buying the radiopharmaceutical therapy company for $4.1 billion to expand its cancer treatment options. It was the second multibillion-dollar acquisition for Bristol Myers Squibb in less than a week.
2023-12-26 11:55:36 - Investopedia
Midday Movers: Intel's Israel Deal, Bristol-Myers Squibb Buys RayzeBio
Christmas may be over, but the so-called “Santa Claus rally” continued for U.S. equities at midday in the shortened final trading week of 2023. The Dow, S&P 500, and Nasdaq were all in positive territory.
2023-12-26 11:33:49 - Proactive Investors
Bristol Myers Squibb goes back to the acquisition well with $4.1B purchase of RayzeBio
Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP) has made its second major acquisition in the span of a week, this time buying cancer drug developer RayzeBio in a $4.1 billion deal. The deal values RayzeBio at $62.50 per share.
2023-12-26 10:10:15 - InvestorPlace
Why Is RayzeBio (RYZB) Stock Up 100% Today?
Shares in RayzeBio (NASDAQ: RYZB ) doubled after Bristol Myers Squibb (NYSE: BMY ) said it will buy it for about $4.1 billion. Bristol Myers is paying $62.50 per share for the cancer drug maker, which is based in San Diego.
2023-12-26 08:55:42 - Fox Business
Bristol Myers to buy RayzeBio for about $4.1B
The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition.